Age-dependent neuromuscular impairment in prion protein knockout mice

Muscle and Nerve

Volumn 53, Issue 2, 2016, Pages 269-279

  Massimino, Maria Lina ^a   Peggion, Caterina ^a   Loro, Federica ^a   Stella, Roberto ^a,b   Megighian, Aram ^a   Scorzeto, Michele ^a   Blaauw, Bert ^a   Toniolo, Luana ^a   Sorgato, Maria Catia ^a   Reggiani, Carlo ^a   Bertoli, Alessandro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE   (Italy)

Author keywords

Demyelination; Prion protein; Sciatic nerve; Skeletal muscle; Treadmill

Indexed keywords

LACTIC ACID; MYELIN; PRION PROTEIN; ADENOSINE TRIPHOSPHATASE; CITRATE SYNTHASE; MYOSIN HEAVY CHAIN; PRION; SUCCINATE DEHYDROGENASE;

AEROBIC EXERCISE; AGED; AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DEMYELINATION; DENSITOMETRY; ENERGY METABOLISM; EXERCISE TOLERANCE; GENOTYPE; IN VIVO STUDY; METABOLIC PARAMETERS; MICROTUBULE; MOUSE; MYELINATED NERVE; NERVE DEGENERATION; NERVE FIBER; NERVE STIMULATION; NEUROMUSCULAR DISEASE; NONHUMAN; PERIPHERAL NERVE; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCIATIC NERVE; SOLEUS MUSCLE; TREADMILL TEST; WESTERN BLOTTING; ACTION POTENTIAL; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; EXERCISE TEST; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOTOR ACTIVITY; MUSCLE STRENGTH; NERVE CONDUCTION; PATHOLOGY; PATHOPHYSIOLOGY; PRION; SKELETAL MUSCLE; SKELETAL MUSCLE CELL;

ACTION POTENTIALS; ADENOSINE TRIPHOSPHATASES; AGING; ANIMALS; CITRATE (SI)-SYNTHASE; DISEASE MODELS, ANIMAL; EXERCISE TEST; GENE EXPRESSION REGULATION; LACTIC ACID; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE FIBERS, SKELETAL; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS; NEURAL CONDUCTION; NEUROMUSCULAR DISEASES; PRIONS; SCIATIC NERVE; SUCCINATE DEHYDROGENASE;

EID: 84969377141     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24708     Document Type: Article

References (47)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363-13383.
2. Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci 2008;31:439-477.
3. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008;88:673-728.
4. Sorgato MC, Peggion C, Bertoli A. Is, indeed, the prion protein a harlequin servant of "many" masters? Prion 2009;3:202-205.
5. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009;457:1128-1132.
6. Büeler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, DeArmond S, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992;356:577-582.
7. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. Mol Neurobiol 1994;8:121-127.
8. Mallucci GR, Ratté S, Asante EA, Linehan J, Gowland I, Jefferys JG, et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. EMBO J 2002;21:202-210.
9. McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, et al. Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 2004;165:227-235.
10. Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, et al. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 2005;20:442-449.
11. Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, et al. Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspasi-3 activation, and exacerbation of ischemic brain injury. Stroke 2006;37:1296-1300.
12. Coitinho AS, Roesler R, Martins VR, Brentani RR, Izquierdo I. Cellular prion protein ablation impairs behavior as a function of age. NeuroReport 2003;14:1375-1379.
13. Nazor KE, Seward T, Telling GC. Motor behavioral and neuropathological deficits in mice deficient for normal prion protein expression. Biochim Biophys Acta 2007;1772:645-653.
14. Rial D, Duarte FS, Xikota JC, Schmitz AE, Dafrè AL, Figueiredo CP, et al. Cellular prion protein modulates age-related behavioral and neurochemical alterations in mice. Neuroscience 2009;164:896-907.
15. Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010;13:310-318.
16. Massimino ML, Redaelli M, Bertoli A, Sorgato MC, Mucignat-Caretta C. Altered behavioral aspects of aged mice lacking the cellular prion protein. Physiol Behav 2013;119:86-91.
17. Nico PB, de-Paris F, Vinadé ER, Amaral OB, Rockenbach I, Soares BL, et al. Altered behavioural response to acute stress in mice lacking cellular prion protein. Behav Brain Res 2005;162:173-181.
18. Miele G, Alejo Blanco AR, Baybutt H, Horvat S, Manson J, Clinton M. Embryonic activation and developmental expression of the murine prion protein gene. Gene Expr 2003;11:1-12.
19. Massimino ML, Ferrari J, Sorgato MC, Bertoli A. Heterogeneous PrPC metabolism in skeletal muscle cells. FEBS Lett 2006;580:878-884.
20. Stella R, Massimino ML, Sandri M, Sorgato MC, Bertoli A. Cellular prion protein promotes regeneration of adult muscle tissue. Mol Cell Biol 2010;30:4864-4876.
21. Klamt F, Dal-Pizzol F, Conte da Frota MJ, Walz R, Andrades ME, da Silva EG, et al. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med 2001;30:1137-1144.
22. Zanetti F, Carpi A, Menabò R, Giorgio M, Schulz R, Valen G, et al. The cellular prion protein counteracts cardiac oxidative stress. Cardiovasc Res 2014;104:93-102.
23. Zanusso G, Vattemi G, Ferrari S, Tabaton M, Pecini E, Cavallaro T, et al. Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. Brain Pathol 2001;11:182-189.
24. Connolly AM, Keeling RM, Mehta S, Pestronk A, Sanes JR. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 2001;11:703-712.
25. Blaauw B, Mammucari C, Toniolo L, Agatea L, Abraham R, Sandri M, et al. Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum Mol Genet 2008;17:3686-3696.
26. Talmadge RJ, Roy RR. Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol 1993;75:2337-2340.
27. Wehling-Henricks M1, Oltmann M, Rinaldi C, Myung KH, Tidball JG. Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy. Hum Mol Genet 2009;18:3439-3451.
28. Chen P, Cescon M, Megighian A, Bonaldo P. Collagen VI regulates peripheral nerve myelination and function. FASEB J 2014;28:1145-1156.
29. Akay T. Long-term measurement of muscle denervation and locomotor behavior in individual wild-type and ALS model mice. J Neurophysiol 2014;111:694-703.
30. Grandis M, Leandri M, Vigo T, Cilli M, Sereda MW, Gherardi G, et al. Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. Exp Neurol 2004;190:213-223.
31. Gundersen K. Determination of muscle contractile properties: the importance of the nerve. Acta Physiol Scand 1998;162:333-341.
32. Walz R, Amaral OB, Rockenbach IC, Roesler R, Izquierdo I, Cavalheiro EA, et al. Increased sensitivity to seizures in mice lacking cellular prion protein. Epilepsia 1999;40:1679-1682.
33. Hoshino S, Inoue K, Yokoyama T, Kobayashi S, Asakura T, Teramoto A, et al. Prions prevent brain damage after experimental brain injury: a preliminary report. Acta Neurochir Suppl 2003;86:297-299.
34. Smith JD, Moylan JS, Hardin BJ, Chambers MA, Estus S, Telling GC, et al. Prion protein expression and functional importance in skeletal muscle. Antioxid Redox Signal 2011;15:2465-2475.
35. Chance PF. Overview of hereditary neuropathy with liability to pressure palsies. Ann NY Acad Sci 1999;883:14-21.
36. Sander S, Nicholson GA, Ouvrier RA, McLeod JG, Pollard JD. Charcot-Marie-Tooth disease: histopathological features of the peripheral myelin protein (PMP22) duplication (CMT1A) and connexin32 mutations (CMTX1). Muscle Nerve 1998;21:217-225.
37. Warner LE, Hilz MJ, Appel SH, Killian JM, Kolodry EH, Karpati G, et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996;17:451-460.
38. Pujol A, Hindelang C, Callizot N, Bartsch U, Schachner M, Mandel JL. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 2002;11:499-505.
39. Merkies IS, Faber CG. Fatigue in immune-mediated neuropathies. Neuromuscul Disord 2012;22(suppl):S203-207.
40. Ramdharry GM, Thornhill A, Mein G, Reilly MM, Marsden JF. Exploring the experience of fatigue in people with Charcot-Marie-Tooth disease. Neuromuscul Disord 2012;22(suppl):S208-213.
41. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol Rev 2011;91:1447-1531.
42. Schantz P, Henriksson J, Jansson E. Adaptation of human skeletal muscle to endurance training of long duration. Clin Physiol 1983;3:141-151.
43. Windisch A1, Gundersen K, Szabolcs MJ, Gruber H, Lømo T. Fast to slow transformation of denervated and electrically stimulated rat muscle. J Physiol 1998;510:623-632.
44. Sugiura T, Matoba H, Miyata H, Kawai Y, Murakami N. Myosin heavy chain isoform transition in ageing fast and slow muscles of the rat. Acta Physiol Scand 1992;144:419-423.
45. Maggs AM, Huxley C, Hughes SM. Nerve-dependent changes in skeletal muscle myosin heavy chain after experimental denervation and cross-reinnervation and in a demyelinating mouse model of Charcot-Marie-Tooth disease type 1A. Muscle Nerve 2008;38:1572-1584.
46. Stevens L, Mounier Y. Evidences for slow to fast changes in the contractile proteins of rat soleus muscle after hindlimb suspension: studies on skinned fibers. Physiologist 1990;33(suppl):S90-91.
47. Hortobágyi T, Dempsey L, Fraser D, Zheng D, Hamilton G, Lambert J, et al. Changes in muscle strength, muscle fibre size and myofibrillar gene expression after immobilization and retraining in humans. J Physiol 2000;524:293-304.